Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) have earned an average rating of “Hold” from the thirteen research firms that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $4.15.
GDRX has been the topic of several research analyst reports. TD Cowen boosted their target price on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of GoodRx from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Leerink Partners set a $5.00 price objective on shares of GoodRx in a research note on Thursday, August 6th. Wells Fargo & Company raised their price objective on shares of GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Barclays boosted their price objective on shares of GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a report on Thursday, August 20th.
Get Our Latest Report on GoodRx
GoodRx Trading Down 3.3%
Insider Transactions at GoodRx
In other news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 1,567,044 shares of company stock valued at $5,471,274 over the last three months. Company insiders own 5.87% of the company’s stock.
Institutional Investors Weigh In On GoodRx
A number of institutional investors and hedge funds have recently modified their holdings of the company. Technology Crossover Management X Ltd. purchased a new position in GoodRx in the 2nd quarter valued at approximately $4,762,000. Algert Global LLC purchased a new stake in GoodRx during the third quarter worth $2,125,000. Marshall Wace LLP boosted its position in GoodRx by 72.1% during the third quarter. Marshall Wace LLP now owns 934,398 shares of the company’s stock worth $3,074,000 after purchasing an additional 391,370 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in GoodRx during the second quarter worth $540,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in GoodRx in the second quarter valued at $500,000. Institutional investors and hedge funds own 63.77% of the company’s stock.
About GoodRx
GoodRx Holdings, Inc. operates a digital healthcare platform that helps consumers in the United States compare prescription medication prices at pharmacies. Its website and mobile app provide free price comparisons and discounts that consumers can use when paying for eligible prescriptions. The company also offers subscription services, including GoodRx Gold, and provides access to telehealth and other care services through GoodRx Care. Its platform connects consumers with pharmacies and healthcare providers, while its services for pharmaceutical companies include programs that help make medications and savings offers available to patients.
Recommended Stories
- Five stocks we like better than GoodRx
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.
